Nejvíce citovaný článek - PubMed ID 11522239
The preparation of dendritic cells (DCs) for adoptive cellular immunotherapy (ACI) requires the maturation of ex vivo-produced immature(i) DCs. This maturation ensures that the antigen presentation triggers an immune response towards the antigen-expressing cells. Although there is a large number of maturation agents capable of inducing strong DC maturation, there is still only a very limited number of these agents approved for use in the production of DCs for ACI. In seeking novel DC maturation agents, we used differentially activated human mast cell (MC) line LAD2 as a cellular adjuvant to elicit or modulate the maturation of ex vivo-produced monocyte-derived iDCs. We found that co-culture of iDCs with differentially activated LAD2 MCs in serum-containing media significantly modulated polyinosinic:polycytidylic acid (poly I:C)-elicited DC maturation as determined through the surface expression of the maturation markers CD80, CD83, CD86, and human leukocyte antigen(HLA)-DR. Once iDCs were generated in serum-free conditions, they became refractory to the maturation with poly I:C, and the LAD2 MC modulatory potential was minimized. However, the maturation-refractory phenotype of the serum-free generated iDCs was largely overcome by co-culture with thapsigargin-stimulated LAD2 MCs. Our data suggest that differentially stimulated mast cells could be novel and highly potent cellular adjuvants for the maturation of DCs for ACI.
- Klíčová slova
- LAD2 human mast cells, adoptive cellular immunotherapy, dendritic cells, maturation,
- MeSH
- adjuvancia imunologická farmakologie MeSH
- buněčná diferenciace účinky léků MeSH
- buněčné kultury metody MeSH
- dendritické buňky cytologie účinky léků imunologie MeSH
- imunoterapie adoptivní * MeSH
- kokultivační techniky MeSH
- lidé MeSH
- mastocyty cytologie účinky léků imunologie MeSH
- monocyty cytologie účinky léků imunologie MeSH
- prezentace antigenu účinky léků imunologie MeSH
- thapsigargin farmakologie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- thapsigargin MeSH